 Jeffery Moran
Concepts (186)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Indoles | 14 | 2018 | 273 | 2.430 |
Why?
| | Naphthalenes | 14 | 2018 | 117 | 2.430 |
Why?
| | Cannabinoids | 10 | 2013 | 103 | 1.900 |
Why?
| | Tandem Mass Spectrometry | 7 | 2014 | 231 | 1.300 |
Why?
| | Glucuronosyltransferase | 8 | 2012 | 122 | 1.180 |
Why?
| | Designer Drugs | 5 | 2013 | 22 | 1.110 |
Why?
| | Biotin | 6 | 2011 | 46 | 1.100 |
Why?
| | Chromatography, Liquid | 7 | 2014 | 229 | 1.090 |
Why?
| | Carnitine | 5 | 2011 | 63 | 0.990 |
Why?
| | Microsomes, Liver | 8 | 2013 | 182 | 0.930 |
Why?
| | Warfarin | 6 | 2011 | 83 | 0.900 |
Why?
| | Urinalysis | 2 | 2014 | 32 | 0.810 |
Why?
| | Cytochrome P-450 Enzyme System | 4 | 2014 | 194 | 0.810 |
Why?
| | Receptor, Cannabinoid, CB1 | 6 | 2013 | 122 | 0.690 |
Why?
| | Glucuronides | 6 | 2012 | 45 | 0.650 |
Why?
| | Anticoagulants | 4 | 2010 | 253 | 0.650 |
Why?
| | Substance-Related Disorders | 5 | 2022 | 594 | 0.560 |
Why?
| | Solid Phase Extraction | 2 | 2013 | 12 | 0.500 |
Why?
| | Metabolomics | 2 | 2013 | 133 | 0.480 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2011 | 326 | 0.460 |
Why?
| | Fentanyl | 1 | 2014 | 33 | 0.440 |
Why?
| | Wounds, Stab | 1 | 2013 | 6 | 0.440 |
Why?
| | Neck Injuries | 1 | 2013 | 21 | 0.430 |
Why?
| | Benzoflavones | 1 | 2013 | 3 | 0.430 |
Why?
| | Sulfaphenazole | 1 | 2013 | 4 | 0.430 |
Why?
| | Self-Injurious Behavior | 1 | 2013 | 28 | 0.430 |
Why?
| | Substance Abuse Detection | 2 | 2022 | 89 | 0.420 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 95 | 0.400 |
Why?
| | Resource Allocation | 1 | 2011 | 16 | 0.390 |
Why?
| | Valerates | 1 | 2011 | 38 | 0.370 |
Why?
| | Leucine | 1 | 2011 | 118 | 0.370 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 74 | 0.360 |
Why?
| | Humans | 34 | 2022 | 50201 | 0.330 |
Why?
| | Oxidation-Reduction | 4 | 2018 | 317 | 0.310 |
Why?
| | Cannabis | 1 | 2011 | 141 | 0.310 |
Why?
| | Analgesics, Opioid | 1 | 2014 | 562 | 0.300 |
Why?
| | Mass Spectrometry | 4 | 2013 | 285 | 0.290 |
Why?
| | Hydroxylation | 6 | 2012 | 61 | 0.270 |
Why?
| | Molecular Structure | 4 | 2013 | 293 | 0.260 |
Why?
| | Kinetics | 6 | 2018 | 634 | 0.250 |
Why?
| | Linoleic Acids | 1 | 2004 | 8 | 0.230 |
Why?
| | Sodium | 1 | 2004 | 91 | 0.220 |
Why?
| | Hallucinogens | 2 | 2013 | 60 | 0.210 |
Why?
| | Cytochrome P-450 CYP1A2 | 2 | 2013 | 38 | 0.210 |
Why?
| | Animals | 12 | 2019 | 13141 | 0.200 |
Why?
| | Sclerotherapy | 1 | 2022 | 46 | 0.190 |
Why?
| | Male | 12 | 2022 | 25572 | 0.190 |
Why?
| | Mitochondria | 2 | 2004 | 398 | 0.190 |
Why?
| | Central Nervous System Stimulants | 2 | 2013 | 205 | 0.190 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2021 | 115 | 0.180 |
Why?
| | Vascular Malformations | 1 | 2022 | 98 | 0.170 |
Why?
| | Heart Arrest | 1 | 2022 | 151 | 0.170 |
Why?
| | Recombinant Proteins | 5 | 2018 | 480 | 0.160 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 228 | 0.160 |
Why?
| | Acetaminophen | 1 | 2021 | 274 | 0.160 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2019 | 167 | 0.150 |
Why?
| | Fetus | 1 | 2019 | 218 | 0.150 |
Why?
| | Buprenorphine | 1 | 2019 | 144 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2019 | 185 | 0.140 |
Why?
| | Protein Binding | 3 | 2013 | 655 | 0.130 |
Why?
| | Receptor, Cannabinoid, CB2 | 2 | 2013 | 57 | 0.130 |
Why?
| | Stereoisomerism | 3 | 2011 | 101 | 0.130 |
Why?
| | Ligands | 2 | 2012 | 203 | 0.120 |
Why?
| | Liver | 2 | 2012 | 1122 | 0.120 |
Why?
| | Female | 9 | 2021 | 26829 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 387 | 0.120 |
Why?
| | Adult | 7 | 2022 | 13486 | 0.120 |
Why?
| | Rats | 3 | 2019 | 3277 | 0.110 |
Why?
| | Pentanones | 1 | 2013 | 7 | 0.110 |
Why?
| | Paper | 1 | 2013 | 15 | 0.110 |
Why?
| | Capsules | 1 | 2013 | 28 | 0.110 |
Why?
| | Powders | 1 | 2013 | 22 | 0.110 |
Why?
| | Methylamines | 1 | 2013 | 17 | 0.110 |
Why?
| | Tablets | 1 | 2013 | 31 | 0.110 |
Why?
| | Alkaloids | 1 | 2013 | 29 | 0.110 |
Why?
| | Tissue Distribution | 1 | 2013 | 166 | 0.110 |
Why?
| | Oleic Acids | 2 | 2004 | 8 | 0.110 |
Why?
| | Benzodioxoles | 1 | 2013 | 41 | 0.110 |
Why?
| | Pyrrolidines | 1 | 2013 | 67 | 0.110 |
Why?
| | Young Adult | 3 | 2022 | 4052 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2013 | 195 | 0.100 |
Why?
| | Pyrans | 1 | 2012 | 16 | 0.100 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.100 |
Why?
| | Deuterium | 1 | 2011 | 43 | 0.100 |
Why?
| | Reference Standards | 1 | 2011 | 52 | 0.100 |
Why?
| | Methamphetamine | 1 | 2013 | 195 | 0.090 |
Why?
| | Glucuronidase | 1 | 2011 | 48 | 0.090 |
Why?
| | Vitamin B Deficiency | 1 | 2011 | 5 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2011 | 97 | 0.090 |
Why?
| | Outpatients | 1 | 2011 | 115 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 378 | 0.090 |
Why?
| | Behavior, Animal | 1 | 2012 | 176 | 0.090 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 270 | 0.090 |
Why?
| | Vitamin B Complex | 1 | 2010 | 22 | 0.090 |
Why?
| | Nutritional Status | 1 | 2011 | 136 | 0.090 |
Why?
| | Mice | 4 | 2012 | 5673 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 871 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 468 | 0.080 |
Why?
| | Phenylalanine | 1 | 2008 | 131 | 0.070 |
Why?
| | Hepatocytes | 1 | 2009 | 179 | 0.070 |
Why?
| | Psychotropic Drugs | 2 | 2022 | 76 | 0.070 |
Why?
| | Models, Biological | 1 | 2011 | 722 | 0.070 |
Why?
| | Time Factors | 2 | 2011 | 2909 | 0.070 |
Why?
| | Brain | 2 | 2012 | 1311 | 0.070 |
Why?
| | Cohort Studies | 1 | 2011 | 1414 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2010 | 1195 | 0.070 |
Why?
| | Oxygen Consumption | 2 | 2004 | 189 | 0.060 |
Why?
| | Prospective Studies | 2 | 2022 | 2396 | 0.060 |
Why?
| | Signal Transduction | 1 | 2011 | 1612 | 0.060 |
Why?
| | Proton-Translocating ATPases | 1 | 2004 | 9 | 0.060 |
Why?
| | Biological Transport, Active | 1 | 2004 | 33 | 0.060 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2004 | 70 | 0.060 |
Why?
| | Kidney Tubules, Proximal | 1 | 2004 | 62 | 0.060 |
Why?
| | Membrane Potentials | 1 | 2004 | 117 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2004 | 82 | 0.060 |
Why?
| | Fluorescent Dyes | 1 | 2004 | 105 | 0.060 |
Why?
| | Rabbits | 1 | 2004 | 376 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2004 | 230 | 0.050 |
Why?
| | Sclerosing Solutions | 1 | 2022 | 15 | 0.050 |
Why?
| | Spodoptera | 1 | 2002 | 5 | 0.050 |
Why?
| | Linoleic Acid | 1 | 2002 | 14 | 0.050 |
Why?
| | Serum Albumin, Bovine | 1 | 2002 | 22 | 0.050 |
Why?
| | Bleomycin | 1 | 2022 | 34 | 0.050 |
Why?
| | Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.050 |
Why?
| | HMGB1 Protein | 1 | 2021 | 16 | 0.050 |
Why?
| | Keratin-18 | 1 | 2021 | 14 | 0.050 |
Why?
| | Body Temperature | 2 | 2012 | 65 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2022 | 57 | 0.050 |
Why?
| | Deficiency Diseases | 2 | 2011 | 13 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2021 | 120 | 0.050 |
Why?
| | Egg White | 2 | 2011 | 6 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 369 | 0.050 |
Why?
| | Adolescent | 2 | 2022 | 6459 | 0.040 |
Why?
| | Binding, Competitive | 2 | 2012 | 94 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2004 | 1587 | 0.040 |
Why?
| | Middle Aged | 3 | 2022 | 12356 | 0.040 |
Why?
| | Pilot Projects | 1 | 2021 | 703 | 0.040 |
Why?
| | Risk | 1 | 2019 | 315 | 0.040 |
Why?
| | Binding Sites | 2 | 2010 | 375 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2019 | 367 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 92 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 181 | 0.040 |
Why?
| | Aged | 2 | 2022 | 9505 | 0.030 |
Why?
| | Child, Preschool | 1 | 2022 | 3896 | 0.030 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2013 | 49 | 0.030 |
Why?
| | CHO Cells | 1 | 2013 | 121 | 0.030 |
Why?
| | Cricetinae | 1 | 2013 | 211 | 0.030 |
Why?
| | Receptors, Opioid, mu | 1 | 2013 | 46 | 0.030 |
Why?
| | Drug and Narcotic Control | 1 | 2012 | 10 | 0.030 |
Why?
| | Drug Users | 1 | 2012 | 17 | 0.030 |
Why?
| | Drug Partial Agonism | 1 | 2012 | 6 | 0.020 |
Why?
| | Drug Antagonism | 1 | 2012 | 8 | 0.020 |
Why?
| | Tissue Banks | 1 | 2011 | 8 | 0.020 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2011 | 33 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2012 | 160 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 2012 | 92 | 0.020 |
Why?
| | Glucuronic Acid | 1 | 2011 | 8 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 2609 | 0.020 |
Why?
| | Metabolic Detoxication, Phase II | 1 | 2011 | 11 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 5203 | 0.020 |
Why?
| | Microsomes | 1 | 2011 | 35 | 0.020 |
Why?
| | Methylmalonyl-CoA Decarboxylase | 1 | 2011 | 5 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2011 | 118 | 0.020 |
Why?
| | Carbon-Carbon Ligases | 1 | 2010 | 7 | 0.020 |
Why?
| | Cell Membrane | 1 | 2012 | 249 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 28 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 309 | 0.020 |
Why?
| | Intestines | 1 | 2011 | 171 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2011 | 217 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6190 | 0.020 |
Why?
| | Lymphocytes | 1 | 2011 | 154 | 0.020 |
Why?
| | Motor Activity | 1 | 2011 | 222 | 0.020 |
Why?
| | Sulfotransferases | 1 | 2010 | 39 | 0.020 |
Why?
| | Child | 1 | 2022 | 6862 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2010 | 192 | 0.020 |
Why?
| | Neurons | 1 | 2012 | 455 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 964 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 1581 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 2002 | 15 | 0.010 |
Why?
| | Thiazoles | 1 | 2002 | 53 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 208 | 0.010 |
Why?
| | Drug Interactions | 1 | 2002 | 208 | 0.010 |
Why?
| | Cell Survival | 1 | 2002 | 590 | 0.010 |
Why?
| | Oxygen | 1 | 2002 | 321 | 0.010 |
Why?
| | Cell Line | 1 | 2002 | 1010 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 1356 | 0.010 |
Why?
|
|
Moran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|